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Background: Stereotactic body radiotherapy (SBRT) is evolving into a standard of care for unresectable lung
nodules. Local control has been shown to be in excess of 90% at 3 years. However, some patients present with
synchronous lung nodules in the ipsilateral or contralateral lobe or metasynchronous disease. In these cases,
patients may receive multiple courses of lung SBRT or a single course for synchronous nodules. The toxicity of such
treatment is currently unknown.
Methods: Between 2006 and 2012, 63 subjects with 128 metasynchronous and synchronous lung nodules were
treated at the Mayo Clinic with SBRT. Demographic patient data and dosimetric data regarding SBRT treatments
were collected. Acute toxicity (defined as toxicity < 90 days) and late toxicity (defined as toxicity > = 90 days) were
reported and graded as per standardized CTCAE 4.0 criteria. Local control, progression free survival and overall
survival were also described.
Results: The median age of patients treated was 73 years. Sixty five percent were primary or recurrent lung cancers
with the remainder metastatic lung nodules of varying histologies. Of 63 patients, 18 had prior high dose external
beam radiation to the mediastinum or chest. Dose and fractionation varied but the most common prescriptions
were 48 Gy/4 fractions, 54 Gy/3 fractions, and 50 Gy/5 fractions. Only 6 patients demonstrated local recurrence.
With a median follow up of 12.6 months, median SBRT specific overall survival and progression free survival were
35.7 months and 10.7 months respectively. Fifty one percent (32/63 patients) experienced acute toxicity, predominantly
grade 1 and 2 fatigue. One patient developed acute grade 3 radiation pneumonitis at 75 days. Forty six percent
(29/63 patients) developed late effects. Most were grade 1 dyspnea. There was one patient with grade 5 pneumonitis.
Conclusion: Multiple courses of SBRT and SBRT delivery after external beam radiotherapy appear to be feasible and
safe. Most toxicity was grade 1 and 2 but the risk was approximately 50% for both acute and late effects.Introduction
Lung SBRT has classically been used to treat solitary
lung lesions in early stage non-small cell lung cancer in
patients who are not candidates for primary curative re-
section [1,2]. Within the last 3 years, SBRT has been
adopted for the treatment of oligometastatic disease in
the lung from varying histologies with 2 year local* Correspondence: dawnowen@med.umich.edu
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unless otherwise stated.control rates ranging from 75-90% [3,4]. Most series on
SBRT for primary lung cancers report that the treatment
of peripheral solitary lung nodules is generally well toler-
ated with minimal grade 3 and no grade 4/5 toxicity
[3,4]. However, the impact of SBRT on the treatment of
multiple lung nodules in a single treatment course or as
a retreatment modality for new isolated lung nodules
has not been well studied.
The low toxicity reported for lung SBRT has led to its
increased use in the oligometastatic and recurrent lung
cancer setting [5,6]. It is generally accepted that healthy
patients with asymptomatic enlarging metastases and
well controlled extrapulmonary disease can be treatedThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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alyzed their experience with treating metasynchronous
and synchronous bilateral lung cancer in 10 patients.
Most patients received two courses of SBRT, one to a
target in each lung, over the course of 2 months. With a
mean follow up of 20.7 months, no patients had more
than grade 2 pulmonary toxicity [7]. A recent series of
15 patients (76 SBRT treated lesions among them) sug-
gested that those with synchronous disease did poorly
while those with metasynchronous multiple pulmonary
nodules had good 2 year overall survival (68%) [8]. Once
again, no patients experienced greater than grade 2 pul-
monary toxicity.
As the clinical use of SBRT expands and its role in
reirradiation increases, it remains unclear how many
courses of lung SBRT are safe, what constitutes a safe
treatment interval, and what factors predict toxicity. Fur-
ther, as SBRT is widely used in asymptomatic patients
with progressive lung metastases/recurrent disease, it is
important to delineate who will benefit as the potential
for harm is great with such large hypofractionated doses
of radiation.
The current study reports on the Mayo Clinic experi-
ence with multiple courses of lung SBRT for synchron-
ous lung nodules and treatment of metasynchronous
isolated lung nodules.
Methods
The Mayo Clinic has prospectively assessed, treated, and
followed 402 patients from January 1, 2008 to August 1,
2012 with SBRT for lung nodules. Of these, 63 patients
received multiple courses of lung SBRT or SBRT follow-
ing high dose external beam radiotherapy (EBRT) to the
mediastinum for 128 sites treated. Information collected
on these patients included: patient age, gender, tumour
histology, number of metastases at simulation, number
of nodules treated, site of lung nodules, synchronous
and metasynchronous treatment, local control, distant
progression, radiographic response to treatment, SBRT
prescription dose, chemotherapy delivery, acute and late
toxicity. Descriptive statistics were performed using the
in house Mayo clinic program JMP (Version 9.01, SAS
Institute Inc., Cary, North Carolina, USA).
Progression free survival, overall survival, and follow
up from the end of SBRT treatment were estimated
using the Kaplan Meier method. Progression free sur-
vival was defined as any local or distant progression fol-
lowing the end of SBRT treatment. Local failure was
defined as in-field progression over serial CT-based
imaging. This study was approved by the Mayo Clinic
Institutional IRB ethics board.
SBRT plans were designed using Eclipse (Varian, Palo
Alto, CA, USA) treatment planning software. All pa-
tients underwent 4DCT planning scans. The ITV wasdefined by contours on 10 phases of respiration. Expan-
sion from ITV to PTV was generally 5 mm circumferen-
tially in all directions. Abdominal compression and
breath hold techniques were employed to minimize mo-
tion in lower lobe tumours. Prior to 2010, most patients
received lung SBRT every other day and planning
was performed using 3DCRT and static field IMRT
techniques. After 2010, VMAT/RapidArc® planning was
more frequently used and treatment was delivered on a
daily basis even in those with previous lung SBRT treat-
ments. Based on our experience and other published re-
ports, we have found no treatment planning effect on
local control or difference in toxicity among all lung
SBRT patients [9,10]. Daily cone beam CT was used to
verify the position of the ITV prior to each treatment
delivery.
A common set of dose volume histogram (DVH) met-
rics were calculated for all patients in the study using an
in-house program, DataMiner. Structures contoured for
DVH analysis included the heart, esophagus, bilateral
lungs, great vessels, spinal cord, trachea, and proximal
bronchial tree as definied by RTOG 0236. Dependencies
of toxicity scores on DVH metrics were examined using
Receiver Operator Characteristics (ROC) curve analysis,
carried out with R (The R Foundation for Statistical
Computing, www.r-project.org). The area under the
ROC curves (ROC AUC) was calculated. For each DVH
metric, a threshold value was determined as the value
maximizing the Youden Index on the ROC curve. The
significance of the association of groups segregated into
2x2 contingency tables according to toxicity and value of
each DVH metric with respect the threshold was calcu-
lated using Fisher’s exact test.
While data was available in a prospectively collected
Mayo Clinic database, all data was verified by retrospect-
ive chart review. Acute and late toxicity data were docu-
mented at every follow up in a prospective manner.
Additional information was gleaned from follow up
notes and notes documenting effects during the treat-
ment course. The standardized CTCAE version 4.03




A total of 128 lung nodules were treated in 63 patients
with lung SBRT during the study period (Table 1). Of
the 63 patients, 18 had received prior chest/mediastinum
radiotherapy before receiving SBRT (median EQD2
EBRT dose received was 60 Gy). More than half of the
patients were female (34/63) and more than half of the
tumours treated were primary lung cancers (41/63).
Mean tumour size was 1.8 cm (range 0.6 to 5.0 cm). Ap-
proximately 1/3 of the tumours were centrally located





Median age at tx 72 (range 20-90)
Histology N=63
Breast cancer 1
Head & neck 5
Non small cell lung cancer 40
Small cell lung cancer 1
Melanoma 4










Central vs peripheral lesion N=128
Central 47
Peripheral 81
Mean tumour diameter (longest dimension) N=128
1.8 cm (range 0.6 to 5.0 cm)
Primary v recurrent v metastatic disease N=128
Primary lung tumour 40
Recurrence after primary SBRT for T1N0 disease 25
Metastatic lung nodules 45



















Table 1 Demographics of multiple courses lung SBRT
patients (Continued)
Number of SBRT courses per patient N=63
1 (synchronous; 2 sites treated at once) 29
2 28
3 6
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50 Gy/5 fractions and 54 Gy/3 fractions. Most patients
had 2 lung nodules (42/63) treated. Of these, 28 patients
had two lung sites treated with consecutive courses of
SBRT separated by one month. The median time between
lung SBRT courses for all patients was 12.9 months (0–113
months). The median time beween lung SBRT and prior
EBRT was 18.4 months (range 1.5-112 months).
Dosimetry
Cumulative lung dose was calculated using sum plans
within the Varian® Eclipse planning software. The cumu-
lative mean lung volume irradiated in all patients was
3363 cc with a mean DC1000cc of 2.9 Gy and DC1500cc
of 8.2 Gy. Mean lung V5 was 43% (median 39%) and
mean V20 was 15% (median 12%). Mean lung dose was
10.1 Gy (median 8.5 Gy). The mean BED received by
both lungs across cumulative SBRT courses was 255 Gy.
Mean heart dose was 9.5 Gy (median 6.0 Gy). Cumula-
tive maximum dose to the chest wall ranged from 25–
142 Gy (median 66 Gy) with a mean D5cc of 58.6 Gy.
Cumulative maximum esophageal dose ranged from 7.1
to 79.4 Gy (median 24.5 Gy). Cumulative D4cc bronchial
tree threshold dose ranged from 0.2-79.6 Gy (median
17.6 Gy).
Acute toxicity
Acute toxicity was any toxicity related to lung SBRT oc-
curring < 90 days from the start of SBRT (Table 2). 51%
of patients (32/63 patients) experienced acute toxicity
with the majority (44 events) grade 2 or less. Half of the
patients with acute toxicity were those who had syn-
chronous lung SBRT courses or consecutive SBRT
courses separated by one month. 40% of the patients
who experienced toxicity had prior lung EBRT; however,
Table 2 Acute toxicity (N = 44 events; N = 32 patients)

















Type of toxicity N=44










Pneumonitis (at 75 days) 1
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toxicity. The most common toxicity was fatigue (16/44).
The median time to acute toxicity was 25 days (range 1–
89 days). There were two grade 3 toxicities: one was ra-
diation pneumonitis requiring hospitalization and the
second was hepatitis requiring hospitalization. The latterwas questionable as the right lower lobe lesion treated in
this case was approximately 2 cm from the liver edge.
On univariate analysis, chemotherapy delivered within
1 month of SBRT (p = 0.03), prior lung EBRT (p = 0.01),
left sided lesions (p = 0.001), and higher BED or EQD2
(p = 0.01), were associated with developing acute tox-
icity. These three factors were not associated with the
development of acute toxicity on multivariate analysis.
No dosimetric variables were correlated with acute
toxicity.
Late toxicity
Median followup from the end of SBRT was 12.6 months
(range 0.5 to 50 months). Nearly half of the patients
(29/63) had some late effects (toxicity arising beyond
90 days from the end of SBRT Table 3). The majority
were less than grade 2 (33/37). Of the 29 patients with
late toxicity, 8 had prior chest EBRT. The most common
late effect was dyspnea. The median time to late toxicity
was 192 days (range 91 to 483 days). Of the three patients
with grade 3 toxicities, two developed severe dyspnea re-
quiring hospitalization and continuous oxygen therapy
afterwards. The third grade 3 toxicity was left vocal cord
paralysis after treatment of a left upper lobe lesion re-
quiring injection of the affected vocal cord. There was
one grade 5 toxicity where a patient died from radiation
pneumonitis (162 days after his last course of SBRT).
None of the patients who developed grade 3 or higher
late toxicity had received prior EBRT to the chest. This
patient had a single right lung nodule radiated to 50 Gy/
5 fractions SBRT and six months later received a course
of lung SBRT to two synchronous nodules (one in the
right upper lobe and another in the left lower lobe). His
first course of SBRT was to a central lesion and the sec-
ond course was to one central and one peripheral lesion.
On univariate analysis, gender (male; p = 0.01), lung
histology (p = 0.03) and number of SBRT sites treated
(p = 0.0001) were associated with late toxicity. None of
these factors were predictive of late toxicity on multivariate
analysis. None of the lung or heart dosimetric parameters
were correlated or predictive of late toxicity.
Local control
Of the 128 sites treated with multiple courses of SBRT,
6/128 showed local recurrence or progression and 110/
128 had stable disease or better. More than half of the
treatment courses, 80/128 had distant progression after
the end of SBRT. Actuarial local control at 2 years was
99.1%. Given the very low failure rate, it was not possible
to examine any factors that predicted for local failure.
Overall survival and progression free survival
Median SBRT overall survival (OS) was 35.7 months (0.6
to 51.0 months) and median SBRT progression free
Table 3 Demographics of late effects (N = 37 events;
N = 29 patients)
Median time to late toxicity 192 days (range 91-483 days)




















5 1 (one patient died of
pneumonitis at d162)
Type of toxicity N=37




Vocal cord paralysis 1
Fatigue 2












Number who had 2 sites treated at
once/split over short period of time
between 2 courses
N=12
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One year overall survival from the end of SBRT treat-
ment was 85% while one year progression free survival
was 91.9%. Histology (primary lung cancer versus meta-
static disease) had no impact on SBRT specific overall
survival. However, SBRT PFS was much higher in pa-
tients with lung cancer than those with oligometastatic
disease (p = 0.0001; median lung cancer SBRT PFS was
15.4 months versus 3.8 months in oligometastatic lung
disease and 12 month SBRT PFS 62.0% in lung patients
versus 10.7% in oligometastatic disease).
Discussion
The current study is one of the largest institutional re-
views of repeated courses of lung SBRT for primary lung
cancers and lung oligometastases. In our study, the local
control rate was 99.1% at 24 months. The low risk of
local recurrence is reflective of the high BED of SBRT
treatment. The largest published series to date on SBRT
treatment of multiple primary lung cancers (74 lesions
treated among 48 patients) noted a crude local control
rate of 93% (only 6 patients failed) with a median follow
up of 24 months [8]. Previous reviews have demon-
strated similar results but with much smaller numbers
(10 patients). One report from the University of
Oklahoma treated 10 patients with 21 synchronous/meta-
chronous inoperable lung tumours with an 18 month local
control rate of 95% [11]. The University of Indiana also
published a series on 10 patients with an 18 month local
control rate of 80% for patients with bilateral multiple bi-
opsy proven non small cell lung cancers [7].
In the oligometastatic setting, little has been published
on multiple courses of SBRT. The largest study to date
is from China and examined 172 lung lesions in 71 pa-
tients treated with SBRT. With a median follow up of
24 months, they noted local control rates of 75% at
2 years [12]. Another study reporting on 61 patients
treated primarily for solitary lung metastases (74% of pa-
tients in this series) of various histologies demonstrated
a 2 year local control rate of 89% [3]. A handful of series
have also compared the local control rates for oligome-
tastatic disease (predominantly colorectal cancer) and
primary lung cancer treated with SBRT. They demon-
strated a statistically worse local control rate for oligo-
metastatic disease (78-82% at 2 years) than primary lung
cancer treated with SBRT (93-98% at 2 years) [4,13,14].
Colorectal cancer has historically been shown to have
worse local control than breast metastases [15,16]. Given
our very low failure rate (only 46 sites failed out of 128),
it was not possible to explore factors that predicted for
worse local control.
Our patient population had an excellent median over-
all survival. Primary lung cancer histology was correlated
with much improved progression free survival in our
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lung cancers generally had disease limited to the lungs
while oligometastatic patients may have had other sys-
temic disease that was quiescent at the time of treat-
ment. In the primary lung cancer setting, it has been
suggested that synchronous tumours do worse than
metachronous tumours treated with SBRT as synchron-
ous tumours at presentation reflect a higher initial dis-
ease burden. Creach et al. noted superior 2 year overall
survival (53% versus 0%) and progression free survival
(68% versus 27%) in SBRT lung patients treated for
metachronous versus synchronous disease [8]. We did
not find any interaction of synchronous versus meta-
chronous tumours on survival in primary lung tumour
patients or those with oligometastatic disease. In the
oligometastatic setting, 2 year overall survival rates of
57- 66% and progression free survival rates of 32.4%
have been reported [3,13]. Our findings are comparable
to these series.
In our patient cohort, there was a 50% chance of de-
veloping early toxicity (defined as ≤ 90 days from the last
day of SBRT treatment). Most of these were grade 1 tox-
icities. In our series, fatigue was the most common
symptom although one patient did develop grade 3 radi-
ation pneumonitis at 75 days. This is consistent with
previous reports on SBRT for primary lung tumours
where grade 1 fatigue was noted in approximately half of
treated patients [17].
Much of the lung SBRT literature has focused on the
risk factors for radiation pneumonitis. We examined risk
factors for all grade 2 and above pulmonary toxicities
(dyspnea, cough, and radiation pneumonitis). In the
current study, we did not find any factor predictive of
late pulmonary toxicity. Prior studies have shown that
central lesions retreated with SBRT may be at increased
risk of toxicity. Peulen et al. reported 3 deaths from
grade 5 hemorrhage secondary to reirradiation with
SBRT of centrally located lesions although in these
cases, the former PTV overlapped the subsequent PTV
by ≥ 50% [18]. Other studies in which individual patients
likely received more than one course of lung SBRT
showed minimal toxicity with no grade 3 acute or late
toxicities [8,12]. One patient in our series succumbed to
respiratory distress at 162 days. It was equivocal whether
this was directly related to his SBRT treatment as he also
had severe underlying COPD but he was still coded as a
potential grade 5 toxicity. Many groups advocate a risk
adapted strategy for central lesions with demonstration
of similar SBRT toxicity profiles between peripheral and
central lesions if central lesions are treated to a lower
BED over a more prolonged fractionated course [19-22].
At the Mayo Clinic, central lesions typically are treated
with a dose of 48 Gy/4 fractions or 50 Gy/5 fractions
and peripheral lesions receive 54 Gy/3 fractions. Thesafest dose for central lesions is still the subject of an
ongoing RTOG trial (0813).
In the current study, we did not find that any lung
dosimetric parameters that were correlated with the de-
velopment of any grade 2 or above pulmonary toxicity.
It was difficult to find any correlation given the low risk
of severe complications. We tried to group complica-
tions together to see if we could find any hypothesis
generating associations. The lack of connection between
DVH analysis and lung toxicity is not surprising given
the clinical equipoise surrounding what lung parameters
are the most salient. Multivariate analyses from a num-
ber of institutions have yielded heterogeneous and non-
congruent dosimetric predictors. The most commonly
studied dosimetric measurements are mean lung dose,
V5, V20, and contralateral lung dose [23,24]. There is
also some evidence that centrally located lesions lead to
higher mean lung doses by virtue of trying to push a
higher dose through more lung [25]. However, other
studies allude to the possibility that patient factors such
as underlying COPD may be more salient or more eso-
teric lung parameters such as V25 may be important
[26,27]. In the end, it is often difficult to ascribe late pul-
monary symptoms to SBRT treatment in the setting of
naturally evolving and progressive COPD.
Most recently, heart dose has emerged as a cause for
concern in lung SBRT. The mechanism of how this re-
lates to the risk of radiation pneumonitis is being eluci-
dated. We did not observe this correlation in our patient
cohort although, interestingly, when patients with prior
lung EBRT were excluded, the mean heart dose was cor-
related with a higher risk of grade 3 or above pulmonary
toxicity. In SBRT planning, we seldom place mean organ
dose constraints and are more likely to limit organs to a
volumetric threshold dose or Dmax. To date, few SBRT
studies have examined the impact of heart dose as a pre-
dictor for radiation pneumonitis. In the setting of locally
advanced lung cancer treated with radical chemoradio-
therapy, some groups have broached the possibility that
heart irradiation is correlated with the development of
radiation pneumonitis. Huang et al. examined the heart
and lung dose volume parameters for 209 patients and
found that the most significant variables associated
with ≥ grade 2 radiation pneumonitis were heart V65
and heart D10 [28]. Lung dosimetric variables minimally
changed the modeling for the risk of radiation pneu-
monitis implying that the heart dose is not simply a sur-
rogate for lung dose. A Chinese study confirmed these
findings showing the mean heart dose and DVH-CV was
correlated with the risk of grade ≥ 2 radiation pneumonitis.
However, this was only significant on univariate analysis
and was no longer predictive on multivariate logistic re-
gression [29]. Animal studies from the Groningen group
have shown that radiation of the heart compromises lung
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cidated [30,31].
The current study shows that multiple courses of lung
SBRT is feasible and that the risk of severe (grade ≥ 2)
pulmonary toxicity is uncommon. However, there are
several limitations including the retrospective nature of
data verification (although patients were entered into a
prospective database), the lack of patient reported out-
comes, and short follow up for greater delineation of late
effects. Patient factors such as baseline pulmonary
function, severity of COPD prior to SBRT, cardiac
comorbidities, and ongoing smoking history were also not
consistently documented. These may also have an impact
on the risk of acute and late effects as well.
Generally, multiple courses of SBRT either for syn-
chronous lung lesions or metachronous lung lesions are
very tolerable. None of the patients who had received
prior lung EBRT developed higher than grade 2 toxicity.
Most toxicity in the acute and late setting were grade 1
with fatigue and dyspnea being the most common symp-
toms. Local control was excellent (in excess of 90% at
2 years) with excellent median overall survival. The
emergence of heart dose as a possible predictor of radi-
ation pneumonitis is interesting and warrants more
investigation as reirradiation of centrally located lung tu-
mours with SBRT may require development of further
risk adapted strategies.
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